Choose 1 option.

The correct answer is B because the product must be enabled for discussion in the visit-detailing experience. Salesforce’s Life Sciences Visit Management developer documentation states that information entered in a provider visit typically includes product details, product messages, presentations, marketing items, and samples. Salesforce Trailhead also explains that Life Sciences Cloud uses product administration and product-message configuration to ensure reps only promote and discuss therapies within approved guardrails.

The scenario says the product exists in Salesforce, but it does not appear when the rep tries to add it to the Product Detailing section during a visit. That means the issue is not product creation; it is visit-discussion eligibility. The consultant should configure Product Discussion Settings in the Visit Administration area so Immunexis is available for product detailing and visit discussions.

Option A is incorrect because Territory Product Alignment Rules determine which products are aligned to territories, but the question specifically says the product must be explicitly enabled for use in visit discussions. Territory alignment alone does not guarantee the product appears in the Product Detailing search. Option C is also incorrect because Visit Record Type Mappings control record-type behavior, not whether a product can be discussed. Therefore, the correct configuration is Product Discussion Settings .